KORU Medical Systems, Inc. (KRMD), a medical technology company, reported financial results for the first quarter ended March 31, 2026, with 22% revenue growth. In addition, the firm reiterated its full-year 2026 guidance.
Company Profile
KORU Medical Systems develops, manufactures, and commercialises subcutaneous infusion solutions primarily for the drug delivery market.
First Quarter Results and FY26 Guidance
For the first quarter of 2026, Net loss shrank to $0.8 million or $0.02 per share from $1.2 million, or $0.03 per share in the prior year.
Total net revenue increased $2.1 million, or 22.1%, to $11.8 million compared to $9.6 million in the prior year period.
As of March 31, 2026, cash and cash equivalents were $8.8 million.
Looking ahead to the full year 2026, the firm reiterated net revenue in the range of $47.5 million and $50.0 million, representing growth of 15% - 22%, and gross margin between 61% - 63%.
KRMD has traded between $2.62 and $6.60 over the last year. The stock closed Wednesday's trade at $4.33.
Following the news, KRMD is up 10.73% at $4.44.
For more such news For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.